The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ontarget before buying a share I go onto my FT account and add it to a virtual portfolio then take a look at the finances and forecasts. The latter not really of use if only one or two agencies providing a forecast but like you I was impressed by the fact that while small EVG does have cash to continue its work for a while yet so took a punt. I might get lucky, I hope others here do too.
There are many recent examples of early stage development deals, and the one most relevant to Evgen would be Blackstone Life Sciences recent $350m strategic investment into Reata, whose pipeline isn't that much more advanced than Evgen's and are also focussed on the Nrf2 pathway, and you could argue that SFX-01 and its analougues could offer wider potential in treating multiple diseases than Reata's two main drugs as SFX-01 is also an avtivator of another key pathway STAT3 highlighted by their outstanding phase 2 breast cancer results and with SFX-01's Covid-19 patient trials imminent, early reporting could be highly likely give that it is pahse 2 and phase 3 combined/concurrent, and so don't see any reson why a strategic investor wouldn't be interested in Evgen at this stage of development....and or an early commercial JV....Gla Holders....Evgen's current ridiculous low £14m market offers tremdous UPside as good news is delivered...Watch this Space!!! ;-)
Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment
June 11, 2020
- Blackstone (NYSE: BX) and Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata”), a clinical-stage biopharmaceutical company, today announced that funds managed by Blackstone Life Sciences (“BXLS”) will lead a $350 million royalty and equity investment in Reata to fund the development and potential commercialization of bardoxolone methyl (“bardoxolone”), an investigational once-daily oral therapy being studied for chronic kidney disease (“CKD”) in Alport syndrome, autosomal dominant polycystic kidney disease (“ADPKD”), and other associated potential future indications. These are severe, life-threatening diseases with few or no effective therapies approved by the U.S. Food and Drug Administration (“FDA”).
https://www.globenewswire.com/news-release/2020/06/11/2046801/0/en/Reata-Pharmaceuticals-Inc-and-Blackstone-Life-Sciences-Announce-350-Million-Strategic-Investment.html
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone and omaveloxolone, target the important transcription factor Nrf2 that promotes restoration of mitochondrial function, reduction of oxidative stress, and inhibition of pro-inflammatory signaling.
The stock has now fallen below my buy-in price.
Glad the stake was a modest one only.
Too much hot air being tossed around by some.
Remember these are very early days.
Yes early-stage pharmas are by nature relatively risky, but EVG has a couple of qualities making it less so than its peers (funding model, wide range of studies backing up the properties of their main candidate) and has a significantly lower market cap than its peers.
Take a longer term view.The mms will take some volume.
Buyers? Me, today in a very modest way. EVG an interesting company at an early and risky stage of development but in this climate the P2/3 trials may not take too long so worth a punt.
Well this is looking like a pile of **** isn't it.
Let's hope Dr Huw can get promoting this company so we can shake off these barstewards dragging the SP down.
Whatever has been going on behind the scenes, orchestrated by Finncap and their friends, i'm certain that their backroom business is almost complete and they're going to let this go big time, especially on the back of a decent Rns...Gl ;-)
Well , we now know who was selling the News ....
Huge volume .... we know the sellers but not yet the buyers :-)
Ps the 400k trade at 4.29pm and the 250k trade that follows were also listed as "non protected portfolio " .......
Mostly buys imho, and I reckon the MM's are holding back the sp as shares are accumulated on the cheap.... the 2.1m trade was listed as " Non Protected Portfolio - A non-protected portfolio transaction" which normally denotes a transaction of a number of stocks dealt with by one market maker at an agreed discount to the market price, and therefore suggests that the share transfer/ accumulation is in full swing imho....although you'll always get sellers into any rise and i wouldn't be surprised if the ex CEO has off loaded a few, he was holding 5m plus plus after his share options were accelerated, he hasn't worked since April as fas we know and so probably is running low on cash.... so can't blame him if he's sold a few. Gl :-)
The Evgen website gives us a list of names but it dates back to July
We should get some TR-1 next week , IMO
Link https://evgen.com/investors/shareholder-information/
Moneymunch,
Any idea on who was selling yesterday ?
Thanks good luck too
Nice one John, i've got a feeling that that 14p will look cheap as chips soon enough...Gl ;-)
I agree Moneymunch! I was so impressed I bought but arrived late 100K sub 14p
Once in a life time opportunity to be in a company with a life saving treatment on phase 2/3 stage...sfx-01, anxious to top up on Monday...
Not too sure John, but i'm fairly certain that this will sail past 15p plus and more this coming Monday as market interest and investor anticipation of Evgen's prospects increases , and then let's see if the new CEO has any material news to report in the coming days to add further value. Gl ;-)
Where can you see this trading at in the next week or so Moneymunch ?
N: Non Protected Portfolio - A non-protected portfolio transaction or a fully disclosed portfolio transaction. Normally a transaction of a number of stocks dealt with by one market maker at an agreed discount to the market price.
https://help.stockopedia.com/technical-guide/prices/faqs/london-stock-exchange-quotes/
The 2.1m trade is listed as "Non protected portfolio, Single protected transaction" which denotes a trade between instituitions, which suggests further evidence of the significant share transfer/accumulation that has been in progress for months, and so maybe disclosure coming soon on what's being going on behind the scenes....Evgen is now very likely to take centre stage with SFX-01's Covid-19 patient trials starting this coming week and with so much more potential material news from the rest of their pipeline, market interest is likely to rise significantly, along with Evgen's sp...and no doubt a re-rate or two as more good news is delivered from the new CEO at the helm......Gl...Exciting times!!! ;-)
Over 15 million shares were traded yesterday , which is circa 12% of the total shares in circulation ....
Huge volume for a modest rise .....
Let’s see where we go from here ....